Mevcut COVID-19 Tedavisine Alternatif Olabilecek İlaçlar ve Kök Hücre Tedavisi
Yıl: 2020 Cilt: 9 Sayı: 3 Sayfa Aralığı: 319 - 328 Metin Dili: Türkçe DOI: 10.5336/pharmsci.2020-76186 İndeks Tarihi: 10-05-2021
Mevcut COVID-19 Tedavisine Alternatif Olabilecek İlaçlar ve Kök Hücre Tedavisi
Öz: Aralık 2019’da Çin’in Wuhan şehrinde tanımlanan ve hızla ya-yılan SARS-CoV-2 virüsü, küresel bir pandemiye yol açmıştır. T.C. Sağlık Bakanlığının önerdiği mevcut tedavi protokolündekiilaçlar (hid-roksiklorokin, azitromisin, lopinavir/ritonavir, favipiravir, tocilizumab) da dâhil olmak üzere, COVID-19 hastalığının tedavisiiçin henüz ka-nıtlanmış bir ilaç yoktur. Bununla birlikte, pek çok molekülün in vitro veya klinik çalışmalarla etkinliği araştırılmaktadır. Arbidol, ribavirin, niklozamit, nitazoksanid, ivermektin gibi antiviral aktivitesi olan ilaç-ların, COVID-19 hastalarındaki etkinliğini değerlendirecek klinik ça-lışmalar başlamıştır. Ayrıca immünomodülatör ve antiinflamatuar etkileri nedeniyle Tip 1 interferonlar, kortikosteroidler, ekulizumab, si-rolimus, bevacizumab, Janus kinaz inhibitörleri, statinler ve kolşisin gibi pek çok ilacın, sitokin fırtınasına bağlı olarak özellikle kritik COVID-19 hastalarında gelişen akut akciğer hasarı ve akut respiratuar distres sendromundaki etkinliği araştırılmaktadır. Bu derlemede, yuka-rıda bahsedilen ilaçlar ve mezenkimal kök hücre tedavisinin etkinliği-nin değerlendirildiğiin vitro ve klinik çalışmalar ele alınmıştır. Klinisyenler, bu çalışmaları yakından takip etmeli ve çalışmaların so-nuçlarına göre mevcut tedavilerin güncellenebileceğini göz önünde bu-lundurmalıdırlar.
Anahtar Kelime: Stem Cell Therapy and Medications That Could Be Alternative to the Current COVID-19 Management
Öz: The SARS-CoV-2 virus, which is identified in Wuhan, China in December 2019 and spread rapidly, caused a global pan-demic. There is currently no proven drug for the treatment of COVID-19 disease, including drugs (hydroxychloroquine, azithromycin, lopinavir/ritonavir, favipiravir, tocilizumab) in the current treatment protocol recommended by the Republic of Turkey Ministry of Health. However, the effectiveness of many molecules is being investigated by in vitro or clinical studies. Clinical trials have started to evaluate the effectiveness of drugs with antiviral activity such as arbidol, rib-avirin, niklozamid, nitazoxanide, ivermectin in COVID-19 patients. In addition, treatment efficacy of type 1 interferons, corticosteroids, eculizumab, sirolimus, bevacizumab, Janus kinase inhibitors, statins and colchicine in acute lung injury and acute respiratory distress syn-drome due to cytokine storm in COVID-19 patients is being investi-gated with clinical trials. In this review, in vitro and clinical studies evaluating the effectiveness of the above mentioned drugs and mes-enchymal stem cell therapy are discussed. Clinicians should follow these studies closely and consider that existing treatments can be up-dated according to the results of the studies.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
- 1. Poutanen SM. Human coronaviruses. In: Long SS, Prober CG, Fischer M, eds. Principles and Practice of Pediatric Infectious Diseases. 5th ed. Philadelphia, PA: Elsevier; 2018. p.1148- 52.e1143.[Crossref] [PMC]
- 2. Shi Z, Wang LF. Evolution of sars coronavirus and the relevance of modern molecular epidemiology. In: Tibayrenc M, ed. Genetics and Evolution of Infectious Diseases. 2nd ed. 2017. p.601-19.[Crossref] [PubMed] [PMC]
- 3. World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV). [Link]
- 4. World Health Organization. Coronavirus dis¬ease (covid-19) pandemic. 2020. Erişim Tarihi: 11.12.20.[Link]
- 5. Chang D, Lin M, Wei L, Xie L, Zhu G, Dela Cruz CS, et al. Epidemiologic and clinical characteristics of novel coronavirus ınfections ınvolving 13 patients outside Wuhan, China. JAMA. 2020;323(11):1092- 3.[Crossref] [PubMed] [PMC]
- 6. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease- 2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924.[Crossref] [PubMed] [PMC]
- 7. Kanne JP. Chest CT findings in 2019 novel coronavirus (2019-nCoV) infections from Wuhan, China: key points for the radiologist. Radiology. 2020;295(1):16-7.[Crossref] [PubMed] [PMC]
- 8. Astuti I, Ysrafil. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): an overview of viral structure and host response. Diabetes Metab Syndr. 2020;14(4):407- 12.[Crossref] [PubMed] [PMC]
- 9. Zheng YY, Ma YT, Zhang JY, Xie X. COVID- 19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259-60.[Crossref] [PubMed] [PMC]
- 10. Verdecchia P, Cavallini C, Spanevello A, Angeli F. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur J Intern Med. 2020;76:14-20.[Crossref] [PubMed] [PMC]
- 11. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586-90. [Crossref] [PubMed] [PMC]
- 12. Zhou D, Dai SM, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. 2020;75(7):1667-70.[Crossref] [PubMed] [PMC]
- 13. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949.[Crossref] [PubMed] [PMC]
- 14. Kim AY, Gandhi RT (authors), Hirsch MS (section editor), Bloom A (deputy editor). Coronavirus disease 2019 (COVID-19): Management in hospitalized adults. UpToDate 2020.[Link]
- 15. Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, et al. Efficacy of hydroxychloroquine in patients with COVID-19: Results of a randomized clinical trial. medRxiv. [Link]
- 16. Shah B, Modi P, Sagar SR. In silico studies on therapeutic agents for COVID-19: Drug repurposing approach. Life Sci. 2020;252:117652. [Crossref] [PubMed] [PMC]
- 17. Khamitov RA, Loginova SIa, Shchukina VN, Borisevich SV, Maksimov VA, Shuster AM. [Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures]. Vopr Virusol. 2008;53(4):9-13. Russian. [PubMed]
- 18. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58-60.[Crossref] [PubMed]
- 19. Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H,et al. Arbidol combined with LPV/r versus LPV/r alone against corona virus disease 2019: a retrospective cohort study. J Infect. 2020;81(1):e1-e5.[Crossref] [PubMed] [PMC]
- 20. Li Y, Xie Z, Lin W, Cai W, Wen C, Guan Y, et al. An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI). MedRxiv. 2020.[Crossref]
- 21. Falzarano D, de Wit E, Martellaro C, Callison J, Munster VJ, Feldmann H. Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. Sci Rep. 2013;3:1686.[Crossref] [PubMed] [PMC]
- 22. Chen F, Chan KH, Jiang Y, Kao RY, Lu HT, Fan KW, et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol. 2004;31(1):69-75.[Crossref] [PubMed] [PMC]
- 23. Chiou HE, Liu CL, Buttrey MJ, Kuo HP, Liu HW, Kuo HT, et al. Adverse effects of ribavirin and outcome in severe acute respiratory syndrome: experience in two medical centers. Chest. 2005;128(1):263-72. [Crossref] [PubMed] [PMC]
- 24. Tai DY. Pharmacologic treatment of SARS: current knowledge and recommendations. Ann Acad Med Singap. 2007;36(6):438- 43.[PubMed]
- 25. Arabi YM, Shalhoub S, Mandourah Y, Al- Hameed F, Al-Omari A, Al Qasim E, et al. Ribavirin and interferon therapy for critically Ill patients with Middle East respiratory syndrome: a multicenter observational study. Clin Infect Dis. 2020;70(9):1837-44.[Crossref] [PubMed] [PMC]
- 26. Omrani AS, Saad MM, Baig K, Bahloul A, Abdul-Matin M, Alaidaroos AY, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis. 2014;14(11):1090-5.Erratum in: Lancet Infect Dis. 2015;211(2):13.[Crossref] [PubMed] [PMC]
- 27. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-71.[Crossref] [PubMed] [PMC]
- 28. Wu CJ, Jan JT, Chen CM, Hsieh HP, Hwang DR, Liu HW, et al. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob Agents Chemother. 2004;48(7):2693-6.[Crossref] [PubMed] [PMC]
- 29. Gassen NC, Niemeyer D, Muth D, Corman VM, Martinelli S, Gassen A, et al. SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-Coronavirus infection. Nat Commun. 2019;10(1):5770.[Crossref] [PubMed] [PMC]
- 30. Jeon S, Ko M, Lee J, Choi I, Byun SY, Park S, Shum D, Kim S. Identification of antiviral drug candidates against SARS-CoV-2 from FDAapproved drugs. Antimicrob Agents Chemother. 2020;64(7):e00819-20.[Crossref] [PubMed] [PMC]
- 31. Tong X, Smith J, Bukreyeva N, Koma T, Manning JT, Kalkeri R, et al. Merimepodib, an IMPDH inhibitor, suppresses replication of Zika virus and other emerging viral pathogens. Antiviral Res. 2018;149:34-40.[Crossref] [PubMed]
- 32. Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583(7816): 459-68. [Crossref] [PubMed] [PMC]
- 33. Bukreyeva N, Mantlo EK, Sattler RA, Huang C, Paessler S, Zeldis J. [The IMPDH inhibitor merimepodib suppresses SARSCoV- 2 replication in vitro]. bioRxiv. 2020. [Crossref]
- 34. Mastrangelo E, Pezzullo M, De Burghgraeve T, Kaptein S, Pastorino B, Dallmeier K, et al. Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug. J Antimicrob Chemother. 2012;67(8):1884- 94.[Crossref] [PubMed] [PMC]
- 35. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787. [Crossref] [PubMed] [PMC]
- 36. Patel AN, Desai SS, Grainger DW, Mehra MR. Usefulness of ivermectin in COVID-19 illness. 2020.[Link]
- 37. Halaclı B, Topelı A. Treatment of the cytokine storm in COVID-19. J Crit Intensive Care. 2020;11(Suppl. 1):36-40.[Crossref]
- 38. Chan JF, Chan KH, Kao RY, To KK, Zheng BJ, Li CP, et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect. 2013;67(6):606- 16.[Crossref] [PubMed] [PMC]
- 39. Chan JF, Yao Y, Yeung ML, Deng W, Bao L, Jia L,et al. Treatment with lopinavir/ritonavir or ınterferon-β1b improves outcome of MERSCoV ınfection in a nonhuman primate model of common marmoset. J Infect Dis. 2015;212(12):1904-13.[Crossref] [PubMed] [PMC]
- 40. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473-5.[Crossref] [PubMed] [PMC]
- 41. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al; Recovery Collaborative Group. Dexamethasone in hospitalized patients with Covid-19 - preliminary report. N Engl J Med. 2020:NEJMoa2021436.[Crossref] [PubMed] [PMC]
- 42. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934-43.[Crossref] [PubMed] [PMC]
- 43. Lin CK, Lin YH, Huang TC, Shi CS, Yang CT, Yang YL. VEGF mediates fat embolism-induced acute lung injury via VEGF receptor 2 and the MAPK cascade. Sci Rep. 2019;9(1):11713.[Crossref] [PubMed] [PMC]
- 44. Zhang Z, Wu Z, Xu Y, Lu D, Zhang S. Vascular endothelial growth factor increased the permeability of respiratory barrier in acute respiratory distress syndrome model in mice. Biomed Pharmacother. 2019;109:2434- 40.[Crossref] [PubMed]
- 45. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.[Crossref] [PubMed] [PMC]
- 46. McNamara LA, Topaz N, Wang X, Hariri S, Fox L, MacNeil JR. High risk for invasive meningococcal disease among patients receiving eculizumab (soliris) despite receipt of meningococcal vaccine. MMWR Morb Mortal Wkly Rep. 2017;66(27):734-7.[Crossref] [PubMed] [PMC]
- 47. Wang R, Xiao H, Guo R, Li Y, Shen B. The role of C5a in acute lung injury induced by highly pathogenic viral infections. Emerg Microbes Infect. 2015;4(5):e28.[Crossref] [PubMed] [PMC]
- 48. Diurno F, Numis FG, Porta G, Cirillo F, Maddaluno S, Ragozzino A, et al. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci. 2020;24(7):4040-7.[Crossref] [PubMed]
- 49. Kindrachuk J, Ork B, Hart BJ, Mazur S, Holbrook MR, Frieman MB, et al. Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis. Antimicrob Agents Chemother. 2015;59(2):1088- 99.[Crossref] [PubMed] [PMC]
- 50. Wang CH, Chung FT, Lin SM, Huang SY, Chou CL, Lee KY, et al. Adjuvant treatment with a mammalian target of rapamycin inhibitor, sirolimus, and steroids improves outcomes in patients with severe H1N1 pneumonia and acute respiratory failure. Crit Care Med. 2014;42(2):313-21.[Crossref] [PubMed]
- 51. Hermans MAW, Schrijver B, van Holten-Neelen CCPA, Gerth van Wijk R, van Hagen PM, van Daele PLA, et al. The JAK1/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release. Clin Exp Allergy. 2018;48(11):1412-20.[Crossref] [PubMed]
- 52. Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20(4):400-2. [Crossref] [PubMed] [PMC]
- 53. Bekerman E, Neveu G, Shulla A, Brannan J, Pu SY, Wang S, et al. Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects. J Clin Invest. 2017;127(4):1338-52.[Crossref] [PubMed] [PMC]
- 54. Fedson DS. Pandemic influenza: a potential role for statins in treatment and prophylaxis. Clin Infect Dis. 2006;43(2):199-205.[Crossref] [PubMed] [PMC]
- 55. Mehrbod P, Omar AR, Hair-Bejo M, Haghani A, Ideris A. Mechanisms of action and efficacy of statins against influenza. Biomed Res Int. 2014;2014:872370.[Crossref] [PubMed] [PMC]
- 56. Yuan S. Statins may decrease the fatality rate of Middle East respiratory syndrome ınfection. mBio. 2015;6(4):e01120.[Crossref] [PubMed] [PMC]
- 57. Rogers AJ, Guan J, Trtchounian A, Hunninghake GM, Kaimal R, Desai M, et al. Association of elevated plasma interleukin-18 level with increased mortality in a clinical trial of statin treatment for acute respiratory distress syndrome. Crit Care Med. 2019;47(8):1089- 96.[Crossref] [PubMed] [PMC]
- 58. Mortensen EM, Restrepo MI, Anzueto A, Pugh J. The effect of prior statin use on 30-day mortality for patients hospitalized with communityacquired pneumonia. Respir Res. 2005;6(1):82.[Crossref] [PubMed] [PMC]
- 59. Hung IF, Wu AK, Cheng VC, Tang BS, To KW, Yeung CK, et al. Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study. Clin Infect Dis. 2005;41(3):291-300.[Crossref] [PubMed]
- 60. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21.[Crossref] [PubMed] [PMC]
- 61. Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. COVID-19 and cardiovascular disease. Circulation. 2020;141(20):1648-55.[Crossref] [PubMed]
- 62. Pharmacists ASoH-S. Assessment of evi¬dence for COVID-19-related treatments. 2020. Erişim Tarihi: 11.12.20.[Link]
- 63. Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, et al. Renin-angiotensin- aldosterone system Inhibitors and risk of Covid-19. N Engl J Med. 2020;382(25):2441-8.[Crossref] [PubMed] [PMC]
- 64. Fowler AA 3rd, Syed AA, Knowlson S, Sculthorpe R, Farthing D, DeWilde C, et al; Medical Respiratory Intensive Care Unit Nursing, Fisher BJ, Natarajan R. Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis. J Transl Med. 2014;12:32. [Crossref] [PubMed] [PMC]
- 65. Fowler AA 3rd, Truwit JD, Hite RD, Morris PE, DeWilde C, Priday A, et al. Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients With Sepsis and Severe Acute Respiratory Failure: The CITRIS-ALI Randomized Clinical Trial. JAMA. 2019;322(13):1261-70.Erratum in: JAMA. 2020;323(4):379.[Crossref] [PubMed] [PMC]
- 66. Shetty AK. Mesenchymal stem cell infusion shows promise for combating coronavirus (COVID-19)- induced pneumonia. Aging Dis. 2020;11(2):462-4.[Crossref] [PubMed] [PMC]
- 67. Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, et al. Transplantation of ACE2- mesenchymal stem cells ımproves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11(2):216-28.[Crossref] [PubMed] [PMC]
- 68. Liang B, Chen J, Li T, Wu H, Yang W, Li Y, et al. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: a case report. Medicine (Baltimore). 2020;99(31):e21429.[Crossref] [PubMed] [PMC]
- 69. Rajarshi K, Chatterjee A, Ray S. Combating COVID-19 with mesenchymal stem cell therapy. Biotechnol Rep (Amst). 2020;26:e00467. [Crossref] [PubMed] [PMC]
- 70. Atluri S, Manchikanti L, Hirsch JA. Expanded umbilical cord mesenchymal stem cells (UCMSCs) as a therapeutic strategy in managing critically Ill COVID-19 patients: the case for compassionate use. Pain Physician. 2020;23(2):E71-83.[PubMed]
| APA | BAHÇECİOĞLU Ö, GÖK S, ARISOY S (2020). Mevcut COVID-19 Tedavisine Alternatif Olabilecek İlaçlar ve Kök Hücre Tedavisi. , 319 - 328. 10.5336/pharmsci.2020-76186 |
| Chicago | BAHÇECİOĞLU ÖMER FARUK,GÖK Selim,ARISOY SEMA Mevcut COVID-19 Tedavisine Alternatif Olabilecek İlaçlar ve Kök Hücre Tedavisi. (2020): 319 - 328. 10.5336/pharmsci.2020-76186 |
| MLA | BAHÇECİOĞLU ÖMER FARUK,GÖK Selim,ARISOY SEMA Mevcut COVID-19 Tedavisine Alternatif Olabilecek İlaçlar ve Kök Hücre Tedavisi. , 2020, ss.319 - 328. 10.5336/pharmsci.2020-76186 |
| AMA | BAHÇECİOĞLU Ö,GÖK S,ARISOY S Mevcut COVID-19 Tedavisine Alternatif Olabilecek İlaçlar ve Kök Hücre Tedavisi. . 2020; 319 - 328. 10.5336/pharmsci.2020-76186 |
| Vancouver | BAHÇECİOĞLU Ö,GÖK S,ARISOY S Mevcut COVID-19 Tedavisine Alternatif Olabilecek İlaçlar ve Kök Hücre Tedavisi. . 2020; 319 - 328. 10.5336/pharmsci.2020-76186 |
| IEEE | BAHÇECİOĞLU Ö,GÖK S,ARISOY S "Mevcut COVID-19 Tedavisine Alternatif Olabilecek İlaçlar ve Kök Hücre Tedavisi." , ss.319 - 328, 2020. 10.5336/pharmsci.2020-76186 |
| ISNAD | BAHÇECİOĞLU, ÖMER FARUK vd. "Mevcut COVID-19 Tedavisine Alternatif Olabilecek İlaçlar ve Kök Hücre Tedavisi". (2020), 319-328. https://doi.org/10.5336/pharmsci.2020-76186 |
| APA | BAHÇECİOĞLU Ö, GÖK S, ARISOY S (2020). Mevcut COVID-19 Tedavisine Alternatif Olabilecek İlaçlar ve Kök Hücre Tedavisi. Literatür Eczacılık Bilimleri Dergisi, 9(3), 319 - 328. 10.5336/pharmsci.2020-76186 |
| Chicago | BAHÇECİOĞLU ÖMER FARUK,GÖK Selim,ARISOY SEMA Mevcut COVID-19 Tedavisine Alternatif Olabilecek İlaçlar ve Kök Hücre Tedavisi. Literatür Eczacılık Bilimleri Dergisi 9, no.3 (2020): 319 - 328. 10.5336/pharmsci.2020-76186 |
| MLA | BAHÇECİOĞLU ÖMER FARUK,GÖK Selim,ARISOY SEMA Mevcut COVID-19 Tedavisine Alternatif Olabilecek İlaçlar ve Kök Hücre Tedavisi. Literatür Eczacılık Bilimleri Dergisi, vol.9, no.3, 2020, ss.319 - 328. 10.5336/pharmsci.2020-76186 |
| AMA | BAHÇECİOĞLU Ö,GÖK S,ARISOY S Mevcut COVID-19 Tedavisine Alternatif Olabilecek İlaçlar ve Kök Hücre Tedavisi. Literatür Eczacılık Bilimleri Dergisi. 2020; 9(3): 319 - 328. 10.5336/pharmsci.2020-76186 |
| Vancouver | BAHÇECİOĞLU Ö,GÖK S,ARISOY S Mevcut COVID-19 Tedavisine Alternatif Olabilecek İlaçlar ve Kök Hücre Tedavisi. Literatür Eczacılık Bilimleri Dergisi. 2020; 9(3): 319 - 328. 10.5336/pharmsci.2020-76186 |
| IEEE | BAHÇECİOĞLU Ö,GÖK S,ARISOY S "Mevcut COVID-19 Tedavisine Alternatif Olabilecek İlaçlar ve Kök Hücre Tedavisi." Literatür Eczacılık Bilimleri Dergisi, 9, ss.319 - 328, 2020. 10.5336/pharmsci.2020-76186 |
| ISNAD | BAHÇECİOĞLU, ÖMER FARUK vd. "Mevcut COVID-19 Tedavisine Alternatif Olabilecek İlaçlar ve Kök Hücre Tedavisi". Literatür Eczacılık Bilimleri Dergisi 9/3 (2020), 319-328. https://doi.org/10.5336/pharmsci.2020-76186 |
